Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment
Powerful chemotherapeutics have been used to combat tumor cells, but serious adverse effects and poor therapeutic efficiency restrict their clinical performance. Herein, we developed reduction-responsive supramolecular hybridized paclitaxel nanoparticles (PTX@HOMNs) for improved tumor treatment. The...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1257788/full |
| _version_ | 1797729230395539456 |
|---|---|
| author | Yuhan Wang Yingli Cui Tinggeng Dai Ying Yue |
| author_facet | Yuhan Wang Yingli Cui Tinggeng Dai Ying Yue |
| author_sort | Yuhan Wang |
| collection | DOAJ |
| description | Powerful chemotherapeutics have been used to combat tumor cells, but serious adverse effects and poor therapeutic efficiency restrict their clinical performance. Herein, we developed reduction-responsive supramolecular hybridized paclitaxel nanoparticles (PTX@HOMNs) for improved tumor treatment. The nanocarrier is composed of F127 and strengthened by a disulfide bond linked organosilica network, which ensures the desirable stability during blood circulation and controlled drug release at tumor sites. The as-prepared PTX@HOMNs could effectively accumulate at tumor regions. After entering tumor cells, PTX@HOMNs can respond to intracellular glutathione, and trigger active drug release for chemotherapy. As a result, PTX@HOMNs exhibited potent antitumor activity against ovarian tumors in vitro and in vivo. Our work provides a deep insight into constructing simple and controlled drug delivery nanoplatforms for improved tumor treatment. |
| first_indexed | 2024-03-12T11:26:07Z |
| format | Article |
| id | doaj.art-6038bfab9b814ccc8c99aabc3e420c83 |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-03-12T11:26:07Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-6038bfab9b814ccc8c99aabc3e420c832023-09-01T07:57:03ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852023-09-011110.3389/fbioe.2023.12577881257788Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatmentYuhan WangYingli CuiTinggeng DaiYing YuePowerful chemotherapeutics have been used to combat tumor cells, but serious adverse effects and poor therapeutic efficiency restrict their clinical performance. Herein, we developed reduction-responsive supramolecular hybridized paclitaxel nanoparticles (PTX@HOMNs) for improved tumor treatment. The nanocarrier is composed of F127 and strengthened by a disulfide bond linked organosilica network, which ensures the desirable stability during blood circulation and controlled drug release at tumor sites. The as-prepared PTX@HOMNs could effectively accumulate at tumor regions. After entering tumor cells, PTX@HOMNs can respond to intracellular glutathione, and trigger active drug release for chemotherapy. As a result, PTX@HOMNs exhibited potent antitumor activity against ovarian tumors in vitro and in vivo. Our work provides a deep insight into constructing simple and controlled drug delivery nanoplatforms for improved tumor treatment.https://www.frontiersin.org/articles/10.3389/fbioe.2023.1257788/fullpaclitaxelorganosilicareduction-responsivecontrolled drug releasechemotherapy |
| spellingShingle | Yuhan Wang Yingli Cui Tinggeng Dai Ying Yue Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment Frontiers in Bioengineering and Biotechnology paclitaxel organosilica reduction-responsive controlled drug release chemotherapy |
| title | Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment |
| title_full | Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment |
| title_fullStr | Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment |
| title_full_unstemmed | Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment |
| title_short | Reduction-responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment |
| title_sort | reduction responsive supramolecular hybridized paclitaxel nanoparticles for tumor treatment |
| topic | paclitaxel organosilica reduction-responsive controlled drug release chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1257788/full |
| work_keys_str_mv | AT yuhanwang reductionresponsivesupramolecularhybridizedpaclitaxelnanoparticlesfortumortreatment AT yinglicui reductionresponsivesupramolecularhybridizedpaclitaxelnanoparticlesfortumortreatment AT tinggengdai reductionresponsivesupramolecularhybridizedpaclitaxelnanoparticlesfortumortreatment AT yingyue reductionresponsivesupramolecularhybridizedpaclitaxelnanoparticlesfortumortreatment |